|
|
 |
|
Viewing report
|
|
|
|
Future Pharmaceutical Industry Trends: Long-term Opportunities Tempered by Short-term challenges
Datamonitor, April 2009, Pages: 184
In recent years, Pharma has begun to adapt its business model in response to growing industry constraints and the decline of the primary-care focused blockbuster therapy. This process of change has recently been disrupted by unprecedented challenges caused by the global economic downturn, and by President Obamas planned overhaul of the US healthcare system.
Scope
- Provides key strategies and trends shaping the future of the pharmaceutical industry
- Examines the impact of the Obama administration on US healthcare, and the implications for Pharma
- Assesses the implications of the current economic and financial situation on healthcare
- Analyzes key growth drivers and resistors set to shape Pharmas future
Highlights of this title
Pharma has begun to implement strategies to evolve from its traditional model towards a new model: Pharma 2.0; defined as a leaner, globalized entity, whose increased scale is achieved virtually rather than through accretion. Pharma 2.0 is focused on targeting high-growth markets through collaboration, and smart sales and marketing strategies.
President Obamas healthcare reform proposals will have a negative impact on Pharmas future growth. While the likely expansion in public healthcare to capture the estimated 15% of the US population who are uninsured will grow future drug revenues, generics companies and eventually biosimilars manufacturers will be the ultimate winners.
The industry now also faces added economic pressures, with Pharma having to implement a swathe of cost-cutting strategies. Also, due to worsening economic conditions in the US, uninsured patients are now even less able to cover the costs of their healthcare, and are making personal cost-cutting, ultimately impacting pharmaceutical sales.
Key reasons to purchase this title
- Gain insight into how the unprecedented challenges of the global recession and President Obamas US healthcare overhaul will affect Pharma
- Understand what strategic steps Pharma companies are implementing to maintain and grow their profitability
- Identify the strategic shifts the Pharma industry is taking in its transition towards Pharma 2.0
Customers who bought this item also bought
The Pharmaceutical Industry 2008: Current and Future Trends and Strategic Issues Shaping Pharma
Bio/Pharma R&D Statistical Sourcebook 2008/2009
New Approaches to Pharma R&D: Evolving Strategies to Rejuvenate R&D Efficiency
Value-Added Pharma: How to Accomplish the Impossible
Biosimilars Series: Forecast Analysis
The Pharmaceutical Market Outlook to 2018: Key Threats and Opportunities for Big Pharma and its Responses to them
The Pharmaceutical Company Outlook to 2012: Strategic Analysis of the Sales Outlook for Big Pharma, Mid Pharma, Japan Pharma and Biotech
Biomarkers and Tests for Pharma/ Biotech R&D – Companies Products and WW Market, 2006-2011
Negotiating the Emerging Biosimilars Landscape: Key Developments in the Regulatory Environment
Meeting the Challenges of Manufacturing Biosimilars
Booming Pharma Sector in India
Biosimilars: A Viable Market - But When?
|
|
|
|
